' 19.2.

2012 - 11
.. . . ,
. . .-
. . .
. , " , .
.
P53 . . ,
, . , .
, , ,
. ,
.

. =
=Tumor , .
.
) (.
. , . . .
. , ,
. . ,

. . .
. ,
. . .
. , . ,
, .
. .
. . ,
,
. low grade dysplasia 90%
. - high grade dysplasia 60% . ,
, .
Carcinoma in situ . . .
stage 0 " .
Carcinuma . .
.
. . ,
.
1

 . .
90 . , .
, .
.
, .
.. . . , 22
, , .
.
. .
.
."
,
.
:
-

, , . ,
, . . ,
. .

,
, ) ( , ,
.
. .
.
.

. ,
. . .

.
.
, .
.
. .
.
, . ,
, ,.

Benign tumor
2

 . - . .
, .
, . . "
." .
. .
. " .
Malignant
.
. . .
. . . .
, . .
. .
.

- Stage 1 ,
- Stage 2
- Stage 3 . .
.
. , .
.
* - :
.
. .
. , , , , , '.
) , , , , (
.
, , - .
.
. ,
= . -
. P53 , .
.. . .. . .
, , .
, .
. ,
3

 . . 4
. , ' , .
- , .well differentiated
, .poorly differentiated -

3 :
-- " " . ,
, .
- , .
.. - .. . : ,
, ) .. (. BRCA- , .. . 60% ,
40% , . . , .
4 . .

.. . . . ...
. -= .
:
. . , ,
, , .
, , , .
) ( , . , .
, .
, , , , , , , , ,
. .
. . -.
.
, . .
.HPV-human papilloma virus ,
. - B=HBV . HCV .
HBV - , . . C
4

 . . , , .
HTLV. . , T H Pilori .
. , ,H Pilori ,
. , . .
HHV8 . .
. HIV - human immunodeficiency virus .
.T )
( , , .
- ,
. . .
.
,= .
. , -
. 50% .
HNPCC FAP .
FAP , . ,
18 . , ,
40 . . .
, .
- - !
...
. , .
.
. , " , ,
.
:
.1 -
.2
.3 . .
: , ,
.1 . .
. . .
.
.2 ,
5

 .3 . .
50 , .
. ,
-.
.4 . .
. .
.

,
. .
, . .
- - , . =) .
( . . , .
, .
, , .
-
. PTH PTH-RP
PTH - ACTH . , .
- , , , ,,
. .
.
.
. , ,
, ,
.
B-Symptoms .B 37.6 -
, , ,
.

.
6

 :
Tumor marker .
. , CEA . .
, , PSA . .
. . .
, ,
.
:
-

40 , .
.

- 40 , ,
.

- . .

PAP ,

,CT, MRI ,
. , .
:
-
, . , ,
.
- , .
:
Cure ALL , 85%. .
stage1 .
- Control - stage4 . 10-15% .
. .
. .
20 . ,
.
7

 CML chronic leukemia . .

.
.
.stage 4 .

, . .

. .
.
. ,
. , . in
situ , . .
.
. , . ,
. .
- . " .
.
.
. , .
, . . . .
. .

:
Grade . -
. grade , , .
Stage , , .
:TMN
- Tumor
- Metastasis
Nodes ,
8

 stages .
- STAGE 4 .
5 . 5 cure. 30%
" !!!
:
, ) , ,
( , , ,
, ,
) , ,( , , ) B, HPV ,12
( , ).(HPV, HBV, Hepatitic C
.
.